Elliot Stieglitz, MD
|School||UCSF School of Medicine|
|Address||1450 3rd Street|
San Francisco CA 94158
|Stony Brook ||School of Medicine||2008|
|New York Presbyterian - Weill Cornell||Pediatric Residency||2011|
|University of California, San Francisco||Pediatric Hematology Oncology Fellowship||2014|
|St. Baldrick's Foundation Fellowship||2014
||2016||Fellow in Clinical Research |
|Alex's Lemonade Stand Foundation||2015
||2017||Young Investigator Award|
Juvenile myelomonocytic leukemia (JMML) is a blood cancer that affects young children and is often difficult to diagnose and treat. Currently available therapies cure only half of patients, with some children experiencing an aggressive disease course while a rare group get better with very little treatment. Unfortunately, we are currently unable to identify these patients at diagnosis.
My first objective is to identify biomarkers associated with a poor prognosis in order to establish a risk stratification algorithm that will prevent using toxic chemotherapy in patients who are predicted not to respond. I am using several next generation sequencing techniques in order to identify these biomarkers including exome sequencing, DNA methylation analysis and droplet digital PCR. Second, with specific biomarkers in place, I can identify targeted medications that would be predicted to improve outcomes for these patients.
Derived automatically from this person's publications.
People in Profiles who have published with this person.
People who share related concepts with this person.